Studies brain scans and biology in early psychosis over a year
Observes adults aged 18 to 40 with early psychosis using brain scans and biological markers.
Key facts
- Who runs it
- Beth Israel Deaconess Medical Center
- Where
- Athens, Belmont, Boston, Chicago, Dallas, and Hartford, United StatesSee the 6 sites
- Trial code
- Registry title
- Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- Status
- Recruiting
- People taking part
- 320 people, planned
- Started
- 1 Jan 2023
- Expected to end
- 30 Jun 2027
- Type of study
- Observational
- Record updated
- 10 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 40 who had a first psychotic illness within the last 4 years and are getting both medicine and talk therapy.
- Age
- 18 to 40 years
- Sex
- Men and women can join.
- Disease stage
- A psychotic disorder (such as schizophrenia, schizoaffective disorder, bipolar I disorder, delusional disorder) that began 4 years ago or less.
- Earlier treatment
- At the start, people must be getting both psychiatric medicine and psychotherapy.
Main reasons for not taking part
- Estimated earlier intellectual ability below 70
- Brain-affecting neurological or medical disorder (for example seizures, stroke, serious head injury, AIDS)
- Psychosis caused by alcohol or drug use
- Cannot read, speak or understand English
- For the MRI scan: pregnancy, metal objects in the body, weight over 300 lbs (136 kg), or fear of closed spaces
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Males and females, all races and ethnicities
- 18-40 y/o
- Meet DSM-5 criteria for a psychotic disorder, i.e. schizophrenia, schizophreniform, schizoaffective disorder, or bipolar I disorder or major depression with psychotic features, delusional disorder or psychosis N.O.S
- Able to read, speak, and understand English
- Able and willing to provide written informed consent, and willing to commit to the study protocol
- Illness duration from psychosis onset less than or equal to 4 years
- At baseline only: receiving both psychopharmacology and psychotherapy
Who cannot take part
- Psychoses secondary to substance use i.e., Comorbid DSM-5 diagnosis of alcohol or substance use disorders that may explain the diagnosis of psychotic disorders (individuals with cannabis use disorders unrelated to psychosis onset will be allowed. Participants encouraged to abstain from substances for 24 hours prior to lab visits); MRI-Specific Exclusion Criteria:
- Neurological or medical disorder that may affect brain function (seizure disorder, traumatic brain injury with a loss of consciousness greater than or equal to 30 min, history of stroke, AIDS, etc.)
- Estimated premorbid intellectual ability <70 (WRAT-4, Word Reading subtest, age-corrected standardized score)
- Pregnant women
- Presence of ferromagnetic objects in body
- Weight or body size exceeding scanner capacity (>300 lbs)
- Claustrophobia
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Where in United States
- University of GeorgiaAthens, United StatesContact: Brett Clementz, PhDTaking people
- McLean HospitalBelmont, United StatesContact: Kathryn E. Lewandowski, PhDTaking people
- Beth Israel Deaconess Medical CenterBoston, United StatesContact: Matcheri S. Keshavan, MDTaking people
- University of Chicago Medical CenterChicago, United StatesContact: Sarah K. Keedy, PhDTaking people
- University of Texas Southwestern Medical CenterDallas, United StatesContact: Carol Tamminga, MDTaking people
- Hartford HospitalHartford, United StatesContact: Godfrey Pearlson, MA, MBBSTaking people
About the trial
What the trial wants to find out
The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder. It involves gathering mental health information, brain scans (MRI), eye movement patterns (Eye-Tracking), and brain electrical waves (EEG) data from individuals who have experienced these disorders in recent years. Participants will be involved for about a year, with four visits over this period. Screening procedures, lasting approximately 3 hours, include tests for drug use, a pregnancy test for eligible women, clinical interviews about feelings and experiences, psychiatric and family history interviews, and a medical history review. Research procedures for eligible participants include DNA collection, a neuropsychological test battery, EEG, eye-tracking, and MRI. These procedures will help researchers understand brain function, genetics, and cognitive abilities related to psychotic disorders. Follow-up visits at 1-month, 6-month, and 12-month intervals involve modified clinical interviews and repeating neuropsychological tests to track changes over time. Participants may opt to provide DNA samples for genetic analysis, undergo various cognitive tests, EEG to record brain waves, eye-tracking to monitor eye movements, and MRI scans to visualize brain structure. Follow-up visits at regular intervals will help researchers track changes in symptoms and cognitive function. This study provides comprehensive insight into the onset and progression of psychotic disorders and offers valuable information for patients, families, and healthcare providers involved in managing these conditions. Our goal is to better understand whether a combination of biological markers and different types of people (BT1, BT2, BT3) can help us predict how well individuals with early psychosis respond to specialized care. We expect that those in BT3 will have the best outcomes, BT2 will have intermediate outcomes, and BT1 will have the poorest outcomes. Even though BT1 and BT2 might start with similar cognitive issues, their biology might lead to different responses to treatment. This research can help us understand which treatments work best for different people with early psychosis.
The group in the trial
- Individuals with Early Psychosis enrolled in Coordinated Specialty Care Clinics
In this naturalistic longitudinal study, we administer the B-SNIP biomarker batter to individuals with Early Psychosis (EP) in EP clinics with Coordinated Specialty Care treatment programs to characterize outcome trajectories and biotypes. EP individuals of both sexes, age 18-40 will be included after they meet study criteria and provide informed consent. Individuals with psychosis duration \< 4 years will be included. Individuals in this cohort of EP are diagnosed with Schizophrenia, Schizoaffective Disorder, Schizophreniform, Bipolar I Disorder with psychotic features, Delusional Disorder, Major Depressive Disorder with psychotic features, and Psychosis Not Otherwise Specified.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- Plain-language title
- Studies brain scans and biology in early psychosis over a yearGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06740383, who can take part
- Record updated
- 10 March 2026